Zydus Lifesciences has entered exclusive negotiations to acquire an 86% stake in Amplitude Surgical, a European leader in lower-limb orthopedic technologies. The deal, valued at €6.25 per share, reflects an 80.6% premium over the company’s last closing price as of March 10, 2025.

Amplitude Surgical specializes in innovative knee and hip prostheses, catering to the needs of patients, surgeons, and healthcare providers. Supported by PAI Partners, the company has witnessed significant growth in recent years, driven by new product development, international expansion, and R&D investments. In the fiscal year ending June 30, 2024, it reported €106 million in sales and an EBITDA of €27.1 million.

Dr. Sharvil Patel, Managing Director of Zydus, emphasized that this acquisition aligns with the company’s commitment to medical technology innovation. By leveraging its expertise in R&D, manufacturing, and quality excellence, Zydus aims to strengthen its foothold in the MedTech sector.

Amplitude Surgical’s CEO, Olivier Jallabert, expressed enthusiasm about joining Zydus, highlighting the company’s 25+ years of industry leadership. PAI Partners also acknowledged the successful transformation of Amplitude Surgical into a European market leader.

With Zydus MedTech’s focus on cutting-edge medical devices, this acquisition marks a strategic expansion into the global medical technology sector, reinforcing Zydus’ position as an innovation-driven healthcare leader.